Cargando…

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berning, Lena, Schlütermann, David, Friedrich, Annabelle, Berleth, Niklas, Sun, Yadong, Wu, Wenxian, Mendiburo, María José, Deitersen, Jana, Brass, Hannah U. C., Skowron, Margaretha A., Hoffmann, Michèle J., Niegisch, Günter, Pietruszka, Jörg, Stork, Björn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957586/ https://www.ncbi.nlm.nih.gov/pubmed/33673611 http://dx.doi.org/10.3390/molecules26051294

Ejemplares similares

The Golgi stacking protein GRASP55 is targeted by the natural compound prodigiosin
por: Berning, Lena, et al.
Publicado: (2023)

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells
por: Sun, Yadong, et al.
Publicado: (2021)

FIP200 controls the TBK1 activation threshold at SQSTM1/p62-positive condensates
por: Schlütermann, David, et al.
Publicado: (2021)

High-throughput screening for natural compound-based autophagy modulators reveals novel chemotherapeutic mode of action for arzanol
por: Deitersen, Jana, et al.
Publicado: (2021)

TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy
por: Wu, Wenxian, et al.
Publicado: (2021)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Systematic analysis of ATG13 domain requirements for autophagy induction
por: Wallot-Hieke, Nora, et al.
Publicado: (2018)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2019)

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2017)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

Efficient recombinant production of prodigiosin in Pseudomonas putida
por: Domröse, Andreas, et al.
Publicado: (2015)

Improved Prodigiosin Production by Relieving CpxR Temperature-Sensitive Inhibition
por: Sun, Yang, et al.
Publicado: (2020)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Natural biocide cocktails: Combinatorial antibiotic effects of prodigiosin and biosurfactants
por: Hage-Hülsmann, Jennifer, et al.
Publicado: (2018)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

The mycotoxin phomoxanthone A disturbs the form and function of the inner mitochondrial membrane
por: Böhler, Philip, et al.
Publicado: (2018)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
por: Knievel, Judith, et al.
Publicado: (2014)

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation
por: Guryanov, Ivan, et al.
Publicado: (2020)

Transcriptional factor OmpR positively regulates prodigiosin biosynthesis in Serratia marcescens FZSF02 by binding with the promoter of the prodigiosin cluster
por: Jia, Xianbo, et al.
Publicado: (2022)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Molecular Analysis of Protein-Protein Interactions in the Ethylene Pathway in the Different Ethylene Receptor Subfamilies
por: Berleth, Mareike, et al.
Publicado: (2019)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Prodigiosin-Emerged PI3K/Beclin-1-Independent Pathway Elicits Autophagic Cell Death in Doxorubicin-Sensitive and -Resistant Lung Cancer
por: Chiu, Wei-Jun, et al.
Publicado: (2018)

Algicidal Effects of Prodigiosin on the Harmful Algae Phaeocystis globosa
por: Zhang, Huajun, et al.
Publicado: (2016)

Prodigiosin - A Multifaceted Escherichia coli Antimicrobial Agent
por: Danevčič, Tjaša, et al.
Publicado: (2016)

Oxidative cyclization of prodigiosin by an alkylglycerol monooxygenase-like enzyme
por: de Rond, Tristan, et al.
Publicado: (2017)

Utilization of Crab Waste for Cost-Effective Bioproduction of Prodigiosin
por: Nguyen, Van Bon, et al.
Publicado: (2020)

Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin
por: Choi, Seong Yeol, et al.
Publicado: (2021)

Bioprocessing of Marine Chitinous Wastes for the Production of Bioactive Prodigiosin
por: Nguyen, Thi-Hanh, et al.
Publicado: (2021)

Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
por: Anwar, Mohammed Moustapha, et al.
Publicado: (2022)

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2
por: Li, Bo, et al.
Publicado: (2019)

In silico exploration of Serratia sp. BRL41 genome for detecting prodigiosin Biosynthetic Gene Cluster (BGC) and in vitro antimicrobial activity assessment of secreted prodigiosin
por: Boby, Farhana, et al.
Publicado: (2023)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g4jugco41mva0290hngoghg7i4